Michelle Yanez - 09 Dec 2024 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Reporting relationship: Chief Financial Officer
Issuer ticker: MIRA
Reported as of: 09 Dec 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Dec 2024, 17:15:37 UTC
Prior SEC filing: 04 Sep 2024
Next SEC filing: 19 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Michelle Yanez

Key filing fact

Michelle Yanez filed Form 4 for MIRA PHARMACEUTICALS, INC. (MIRA) on 10 Dec 2024.

Key facts

This page summarizes Michelle Yanez's Form 4 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Dec 2024, 17:15.

Change

Previous filing in this sequence was filed on 04 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIRA transaction Derivative

Stock Options (right to buy)

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 09 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $1.19
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024.

Footnote F2

The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

Footnote F3

Represents 150,000 stock options that were issued to the Reporting Person on December 6, 2024, that vest in equal halves on the six- and 12-month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $1.19 each.